Oculis Holding AG

NASDAQ:OCSHealthcare · Biotechnology

Mkt Cap$417.31M

Float44.24M

Shares O/S55.72M

Inst Own37.9%

SI4.0%

Dilution

CLOSED · Nov 6+9.66%$7.49

CLOSED · Nov 6

Prev close$6.83+9.66%Close$7.490.00%AH close$7.49

VOL404K$ Vol$2.99MRVOL1.17x

AH$7.49+0.00%vs close

Mkt Cap$417.31M

Float44.24M

O/S55.72M

VOL404K sh

$ Vol$2.99M

RVOL1.17×

Inst Own37.9%

SI4.0%

Dilution

NASDAQ:OCSClosed$7.49+9.66%

MCap$417.31M

Float44.24M

O/S55.72M

VOL404K sh$ Vol$2.99MRVOL1.17×

SI4.0%

Inst Own37.9%

Dilution

Historical Data

Date	Open	High	Low	Close	Volume
Nov 6, 2026	6.83	7.64	6.81	7.49	404,086
Nov 5, 2026	7.30	7.85	6.78	6.83	371,649
Nov 4, 2026	7.60	7.89	6.80	7.28	550,216
Nov 3, 2026	7.72	7.87	7.29	7.63	541,789
Nov 2, 2026	8.38	8.54	7.66	7.71	246,352
Oct 30, 2026	8.19	8.84	8.19	8.26	309,704
Oct 29, 2026	8.09	8.53	8.09	8.24	263,729
Oct 28, 2026	7.80	8.05	7.72	7.98	220,032
Oct 27, 2026	7.92	8.14	7.68	7.83	189,294
Oct 26, 2026	7.88	8.03	7.65	7.96	206,966
Oct 23, 2026	8.04	8.07	7.82	7.90	294,728
Oct 22, 2026	7.77	8.31	7.72	8.09	427,888
Oct 21, 2026	7.54	8.02	7.40	7.87	324,101
Oct 20, 2026	7.29	7.79	7.29	7.49	318,680
Oct 19, 2026	7.25	7.46	7.15	7.32	288,390
Oct 16, 2026	7.33	7.46	7.16	7.29	293,703
Oct 15, 2026	7.25	7.60	7.15	7.40	559,213
Oct 14, 2026	7.51	7.74	7.11	7.17	517,710
Oct 13, 2026	7.84	7.84	7.32	7.62	320,226
Oct 12, 2026	8.27	8.33	7.85	7.88	283,960

Analyst Coverage

ConsensusBuy

Price Target

Not available

Ratings Distribution

BUY

HOLD

SELL

TOTAL9

Insider Trades

No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.

Shareholders

37.9%

Institutional

(66)

0.0%

Insiderⓘ

(0)

12.5%

5%+ Owners

(1)

49.7%

Unattributed (incl. retail)ⓘ

Institutional37.9%

5%+ Beneficial12.5%

Unattributed (incl. retail)49.7%

Top Shareholders

Name	Shares	%	Source
EQT Fund Management S.a r.l.	7.0M	12.5%	13F
LSP 7 Cooperatieve U.A. · joint filing· may incl. warrants· filed Apr 2026	7.0M	12.5%	13G
MILLENNIUM MANAGEMENT LLC	2.0M	3.7%	13F
Pivotal bioVenture Partners Investment Advisor LLC	1.5M	2.7%	13F
CITADEL ADVISORS LLC	987.2K	1.8%	13F
BRAIDWELL LP	834.2K	1.5%	13F
PERCEPTIVE ADVISORS LLC	808.8K	1.5%	13F
Saturn V Capital Management LP	684.9K	1.2%	13F
SR ONE CAPITAL MANAGEMENT, LP	641.0K	1.2%	13F
Siren, L.L.C.	625.0K	1.1%	13F

Sources: 13F, 13D/13GO/S: 55.7M · checked 8 Nov 2026 · market-data provider

Insiders & Institutional Holders

Top institutional holders

About

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye.

The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

The company is based in Zug, Switzerland.

Key Metrics

Market Cap$417.31M

Enterprise Value--

P/E Ratio-10.45

Est. Net Cash/Share--

Institutional Ownership37.87%

based on 55.72M shares outstanding

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

Country

IPO DateMay 18, 2021

Shares Outstanding55.72M

Authorized Shares

Float44.24M

52-Week Range

$6.78$34.48

$7.49(3rd percentile)

Volume

Average Daily Volume346.62K

404.09K today vs 346.62K avg(+17%)

30d Avg

346.62K

60d Avg

317.28K

90d Avg

265.39K

Earnings

Dividend History

No dividend history available

Compliance Status